IXIARO® updated: Overview of clinical trials and developments with the inactivated vaccine against Japanese encephalitis

Expert Review of Vaccines

Volumn 12, Issue 8, 2013, Pages 859-869

  Jelinek, Tomas ^a  

^a Berlin Center for Travel and Tropical Medicine   (Germany)

Author keywords

IC51; IXIARO ; Japanese encephalitis

Indexed keywords

HAVRIX 720; HEPATITIS A VACCINE; INACTIVATED VACCINE; JAPANESE ENCEPHALITIS VACCINE; MENINGOCOCCUS VACCINE; PLACEBO; PNEUMOCOCCUS VACCINE; RABIES VACCINE; TYPHOID VACCINE; UNCLASSIFIED DRUG; YELLOW FEVER VACCINE; VIRUS ANTIBODY;

AGING; ALLERGIC REACTION; ANTIBODY TITER; ARTICLE; ASIA; BRONCHITIS; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; IMMUNOGENICITY; INCIDENCE; INJECTION SITE PAIN; INJECTION SITE REACTION; JAPANESE ENCEPHALITIS; JAPANESE ENCEPHALITIS VIRUS; MYALGIA; NEUROLOGIC DISEASE; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHINOPHARYNGITIS; SINUSITIS; SKIN REDNESS; URINARY TRACT INFECTION; URTICARIA; VACCINATION; VERO CELL; ADOLESCENT; BLOOD; CHILD; CLINICAL TRIAL (TOPIC); DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENCEPHALITIS, JAPANESE; IMMUNOLOGY; INFANT; PATHOLOGY; PRESCHOOL CHILD; ADVERSE DRUG REACTION; REVIEW;

ADOLESCENT; ANTIBODIES, VIRAL; ASIA; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENCEPHALITIS, JAPANESE; HUMANS; INFANT; JAPANESE ENCEPHALITIS VACCINES; PRODUCT SURVEILLANCE, POSTMARKETING; VACCINES, INACTIVATED;

EID: 84887712899     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2013.835638     Document Type: Article

References (36)

1. Halstead SB, Jacobsen J. Japanese encephalitis vaccines. In: Vaccines. 6th Edition. Plotkin SA, Orenstein WA, Offit P (Eds). Saunders Elsevier, PA, USA (2012
2. Japanese encephalitis vaccines: WHO position paper. Wkly Epidemiol. Rec. 81, 331-340 (2006
3. Campbell GL, Hills SL, Fischer M et al. Estimated global incidence of Japanese encephalitis: A systematic review. Bull. World Health Organ. 89, 766A-774E (2011
4. Solomon T, Thao TT, Lewthwaite P et al. A cohort study to assess the new WHO Japanese encephalitis surveillance standards. Bull. World Health Organ. 86, 178-186 (2008
5. Tsarev SA, Sanders ML, Vaughn DW et al. Phylogenetic analysis suggests only one serotype of Japanese encephalitis virus. Vaccine 18(Suppl. 2), 36-43 (2000
6. Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: The spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat. Med. 10(12), S98-S109 (2004
7. Lyons A, Kanesa-thasan N, Kuschner RA et al. A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis. Vaccine 25(17), 3445-3453 (2007
8. Srivastava AK, Putnak JR, Lee SH et al. A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine 19(31), 4557-4565 (2001
9. Ni H, Burns NJ, Chang GJ et al. Comparison of nucleotide and deduced amino acid sequence of the 5' non-coding region and structural protein genes of the wild-type Japanese encephalitis virus strain SA14 and its attenuated vaccine derivatives. J. Gen. Virol. 75(Pt 6), 1505-1510 (1994
10. Hombach J, Solomon T, Kurane I et al. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 23(45), 5205-5211 (2005
11. Tauber E, Kollaritsch H, Korinek M et al. Safety and immunogenicity of a Vero-cellderived, inactivated Japanese encephalitis vaccine: A non-inferiority, Phase III, randomized controlled trial. Lancet 370(9602), 1847-1853 (2007
12. Schuller E, Jilma B, Voicu V et al. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 six and 12 month results of a multicenter follow-up Phase 3 study. Vaccine 26(34), 4382-4386 (2008
13. Van Gessel Y, Klade CS, Putnak R et al. Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO®) induced neutralizing antibody titers. Vaccine 29, 5925-5931 (2011
14. Schuller E, Klade CS, Wolfl G et al. Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: A randomized, observer-blind, controlled Phase 3 study. Vaccine 27(15), 2188-2193 (2009
15. Schuller E, Klade CS, Heinz FX et al. Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralizing antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51. Vaccine 26(48), 6151-6156 (2008
16. Dubischar-Kastner KL, Eder S, Jilma B et al. Persistence of antibodies 60 months after vaccination with the inactivated Japanese encephalitis vaccine IXIARO®, IC51 (Abstract LB-2357). Presented at: The ASTMH 60th Annual Meeting. PA, USA, 4-8 December 2011.
17. Hammon WM, Sather GE. Passive immunity for arbovirus infection. I. Artificially induced prophylaxis in man and mouse for Japanese (B) encephalitis. Am. J Trop. Med. Hyg. 22(4), 524-534 (1973
18. Dubischar-Kastner K, Eder S, Buerger V et al. Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine Ixiaro®, IC51. Vaccine 28, 5197-5202 (2010
19. Eder S, Dubischar-Kastner K, Firbas C et al. Long-term immunity following a booster dose of the inactivated Japanese encephalitis vaccine Ixiaro®, IC51. Vaccine 98, 2607-2612 (2011
20. Erra EO, Askling HH, Rombo L et al. A single dose of vero cell-derived Japanese Expert R encephalitiy (JE) vaccine (Ixiaro) effectively boosts imunity in travelers primed with mouse brain-derived JE vaccines. Clin. Infect. Dis. 55(6), 825-834 (2012
21. Erra EO, Askling HH, Yoksan S et al. Cross-protective capacity of Japanese encephalitis (JE) vaccines against circulating heterologous JE virus genotypes. Clin. Infect. Dis. 56(2), 267-270 (2013
22. Woolpert T, Staples JE, Faix DJ et al. Immunogenicity of one dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine. Vaccine 30(20), 3090-3096 (2012
23. Kaltenböck A, Dubischar-Kastner K, Eder G et al. Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX®1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study. Vaccine 27(33), 4483-4489 (2009
24. Dubischar-Kastner K, Cramer JP, Eder S et al. Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO®, IC51, in elderly (Abstract). Presented at: The 13th Conference of the International Society of Travel Medicine. Maastricht, The Netherlands, 19-23 May 2013.
25. Duggan ST, Plosker GL. Japanese encephalitis vaccine (inactivated, adsorbed) [IXIARO]. Drugs 69(1), 115-122 (2009
26. Schuller KT, Klade C, Kaltenboeck A et al. First clinical trial of a Vero cell derived, inactivated Japanese encephalitis (JE) vaccine IC51 in pediatric population. Presented at: The ASTMH Annual Meeting. New Orleans, LA, USA, 7-11 December 2008.
27. Kaltenböck A, Dubischar-Kastner K, Schuller E et al. Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age. Vaccine 28(3), 834-839 (2010
28. Dubischar-Kastner K, Kadlecek V, Eder S et al. Safety and immunogenicity of the inactivated Japanese encephalitis vaccine Ixiaro®, IC51, in Filipino children aged 2 months to
29. Dubischar-Kastner K, Hatzenbichler E, Cramer J et al. Interim safety and immunogenicity data for the inactivated Japanese encephalitis vaccine IXIARO®, IC51, in children from JE non-endemic countries. Presented at: The 9th Asia Pacific Travel Health Conference. Singapore, 2-5 May 2012.
30. Dubischar-Kastner K, Kaltenboeck A, Schuller E et al. Six months safety of a Vero-cell derived Japanese encephalitis vaccine, IXIARO, IC51, across Phase 3 trials and in a long term follow up cohort. Presented at: The ASTMH Annual Meeting. New Orleans, LA, USA, 7-11 December 2008 (Abstract 836
31. Tauber E, Kollaritsch H, von Sonnenburg F et al. Randomized, double-blind, placebocontrolled Phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J. Infect. Dis. 198(4), 493-499 (2008
32. Schuller E, Klingler A, Dubischar-Kastner K et al. Safety profile of the Vero cellderived Japanese encephalitis virus (JEV) vaccine IXIARO®. Vaccine 29(47), 8669-8676 (2011
33. Jelinek T. Japanese encephalitis vaccine in travelers. Expert Rev. Vaccines 7(5), 689-693 (2008
34. Jelinek T. Ixiaro: A new vaccine against Japanese encephalitis. Expert Rev. Vaccines 8(11), 1501-1511 (2009
35. Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 42(RR 1), 1-15 (1993
36. Kollaritsch H, Paulke-Korinek M, Dubischar-Kastner K. IC51 Japanese encephalitis vaccine. Expert Opin. Biol. Ther. 9(7), 921-931 (2009